Repositorio Dspace

Towards an Optimized Fetal DHA Accretion: Differences on Maternal DHA Supplementation Using Phospholipids vs. Triglycerides during Pregnancy in Different Models

Mostrar el registro sencillo del ítem

dc.contributor.author Gázquez, Antonio
dc.contributor.author Larque, Elvira
dc.date.accessioned 2025-11-18T12:53:55Z
dc.date.available 2025-11-18T12:53:55Z
dc.date.issued 2021-02
dc.identifier.citation Gázquez A, Larqué E. Towards an Optimized Fetal DHA Accretion: Differences on Maternal DHA Supplementation Using Phospholipids vs. Triglycerides during Pregnancy in Different Models. Nutrients. 4 de febrero de 2021;13(2):511.
dc.identifier.uri https://sms.carm.es/ricsmur/handle/123456789/21068
dc.description.abstract Docosahexaenoic acid (DHA) supplementation during pregnancy has been recommended by several health organizations due to its role in neural, visual, and cognitive development. There are several fat sources available on the market for the manufacture of these dietary supplements with DHA. These fat sources differ in the lipid structure in which DHA is esterified, mainly phospholipids (PL) and triglycerides (TG) molecules. The supplementation of DHA in the form of PL or TG during pregnancy can lead to controversial results depending on the animal model, physiological status and the fat sources utilized. The intestinal digestion, placental uptake, and fetal accretion of DHA may vary depending on the lipid source of DHA ingested by the mother. The form of DHA used in maternal supplementation that would provide an optimal DHA accretion for fetal brain development, based on the available data obtained most of them from different animal models, indicates no consistent differences in fetal accretion when DHA is provided as TG or PL. Other related lipid species are under evaluation, e.g., lyso-phospholipids, with promising results to improve DHA bioavailability although more studies are needed. In this review, the evidence on DHA bioavailability and accumulation in both maternal and fetal tissues after the administration of DHA supplementation during pregnancy in the form of PL or TG in different models is summarized.
dc.language.iso eng
dc.publisher MDPI
dc.rights Atribución-NoComercial-SinDerivadas 3.0 España
dc.rights.uri http://creativecommons.org/licenses/by-nc-nd/3.0/es/ *
dc.subject.mesh Animals
dc.subject.mesh Dietary Supplements
dc.subject.mesh Disease Models, Animal
dc.subject.mesh Docosahexaenoic Acids/metabolism
dc.subject.mesh Female
dc.subject.mesh Fetus/metabolism
dc.subject.mesh Humans
dc.subject.mesh Mice
dc.subject.mesh Mothers
dc.subject.mesh Phospholipids/administration & dosage
dc.subject.mesh Pregnancy
dc.subject.mesh Prenatal Care/methods
dc.subject.mesh Rats
dc.subject.mesh Swine
dc.subject.mesh Triglycerides/administration & dosage
dc.title Towards an Optimized Fetal DHA Accretion: Differences on Maternal DHA Supplementation Using Phospholipids vs. Triglycerides during Pregnancy in Different Models
dc.type info:eu-repo/semantics/article
dc.identifier.pmid 33557158
dc.relation.publisherversion https://www.mdpi.com/2072-6643/13/2/511
dc.identifier.doi 10.3390/nu13020511
dc.journal.title Nutrients
dc.identifier.essn 2072-6643


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución-NoComercial-SinDerivadas 3.0 España Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución-NoComercial-SinDerivadas 3.0 España

Buscar en DSpace


Búsqueda avanzada

Listar

Mi cuenta